Related Experiment Video
Updated: Jun 28, 2026

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
Gouty kidney disease: a tubulointerstitial paradigm reimagined-early detection, precision stratification, and
Li-Min Liu1, Li Qin2, Feng Shao2
1Department of Rheumatology and Immunology, Huzhou Third Municipal Hospital, 2088 East Tiaoxi Road, Wuxing District, Huzhou, 313000, Zhejiang, China. 380693081@qq.com.
Insights
Gouty kidney disease damages tubules, missed by standard tests. A new Tubular Risk Stratification (TRS) system and biomarkers may improve early detection and management of this chronic kidney disease subtype.
Area of Science:
- Nephrology
- Urology
- Internal Medicine
Background:
- Gouty kidney disease, a chronic kidney disease (CKD) subtype, involves tubulointerstitial injury from urate crystals.
- Current assessments like estimated glomerular filtration rate (eGFR) and albuminuria fail to detect early tubular damage.
- Specific risk stratification tools for gouty kidney disease are currently unavailable.
Purpose of the Study:
- To review current literature on gouty kidney disease, focusing on early tubular injury detection and risk stratification.
- To identify potential tubular biomarkers and therapeutic strategies for gout-related CKD.
- To propose a conceptual framework for risk stratification in gouty kidney disease.
Main Methods:
- Comprehensive literature search from January 2000 to June 2026 using major scientific databases (PubMed, Scopus, Web of Science, etc.).
- Keywords included: gouty kidney disease, tubular biomarkers, SGLT2 inhibitors, and risk stratification.
- Systematic review and synthesis of findings related to early tubular injury markers and management strategies.
Main Results:
- Renal resistive index (RI), urinary α1-microglobulin, and eGFR slope show promise for detecting early tubular damage in gouty kidney disease.
- SGLT2 inhibitors demonstrate renoprotective effects and mild urate-lowering capabilities, beneficial for gout-related CKD.
- An exploratory, unvalidated Tubular Risk Stratification (TRS) system is proposed.
Conclusions:
- A tubule-centered approach, utilizing novel biomarkers and potentially SGLT2 inhibitors, may enhance early detection and management of gouty kidney disease.
- The proposed Tubular Risk Stratification (TRS) system, if validated, could facilitate risk-stratified clinical care for patients with gout-related renal injury.
Abstract:
Gouty kidney disease is a subtype of chronic kidney disease (CKD) featuring tubulointerstitial injury caused by urate crystal deposition. Conventional assessments using eGFR and albuminuria cannot detect early tubular damage. Risk stratification tools specific to this condition are lacking. We performed a comprehensive literature search from January 2000 to June 2026 across PubMed, Scopus, Web of Science, DOAJ, CNKI, and Wanfang Data. Keywords included gouty kidney disease, tubular biomarkers, SGLT2 inhibitors, and risk stratification. Renal resistive index (RI), urinary α1-microglobulin, and eGFR slope show potential for identifying early tubular injury. SGLT2 inhibitors provide renoprotective and mild urate-lowering effects relevant to gout-related CKD. The Tubular Risk Stratification (TRS) system is proposed as an exploratory, unvalidated conceptual model. A tubule-centred strategy may improve early detection and management of gout-related renal injury. If validated, the TRS system could support risk-stratified clinical care.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury II: Pathophysiology
